B. Metzler seel. Sohn & Co. AG Reduces Stock Position in BridgeBio Pharma, Inc. $BBIO

B. Metzler seel. Sohn & Co. AG trimmed its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 32.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,751 shares of the company’s stock after selling 11,852 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in BridgeBio Pharma were worth $1,286,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BBIO. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $25,000. Aster Capital Management DIFC Ltd acquired a new position in BridgeBio Pharma during the third quarter worth $31,000. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma during the first quarter worth $35,000. First Horizon Corp purchased a new stake in BridgeBio Pharma during the third quarter worth $36,000. Finally, Huntington National Bank grew its holdings in BridgeBio Pharma by 111.7% in the third quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after purchasing an additional 392 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: JPMorgan raised its price target to $94 and kept an “overweight” rating, implying meaningful upside from current levels; this large-bank upgrade likely boosted investor demand. JPMorgan raises price target
• Positive Sentiment: William Blair initiated coverage with an “outperform” rating, adding institutional analyst support and fresh buy-side attention. William Blair starts coverage
• Positive Sentiment: HC Wainwright revised estimates aggressively, forecasting FY2027 EPS of $1.83 and maintaining a $100 target — another high-profile bullish projection that supports investor optimism. HC Wainwright estimate
• Positive Sentiment: Media coverage is highlighting BridgeBio’s rare-disease pipeline as a growth catalyst, which can lift sentiment and attract speculative interest in the biotech name. BridgeBio pipeline article
• Neutral Sentiment: Reports flagged a “large increase” in short interest, but the published data shows zero shares/NaN and a days-to-cover of 0.0 — the short-interest figures appear erroneous or incomplete, so they offer no clear directional signal today.

BridgeBio Pharma Trading Up 13.2%

BridgeBio Pharma stock opened at $74.32 on Wednesday. The stock has a 50-day moving average price of $73.42 and a 200 day moving average price of $65.74. BridgeBio Pharma, Inc. has a 52 week low of $28.33 and a 52 week high of $84.94. The stock has a market cap of $14.41 billion, a PE ratio of -19.66 and a beta of 1.13.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million for the quarter, compared to the consensus estimate of $150.71 million. During the same quarter last year, the business posted ($1.40) EPS. The company’s quarterly revenue was up 2521.2% compared to the same quarter last year. On average, equities analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Insider Buying and Selling at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total transaction of $2,877,600.00. Following the sale, the chief executive officer owned 695,686 shares in the company, valued at approximately $50,047,650.84. This trade represents a 5.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $75.46, for a total transaction of $754,600.00. Following the completion of the sale, the director directly owned 11,589 shares of the company’s stock, valued at $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 227,095 shares of company stock valued at $16,099,240. 18.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BBIO has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. JPMorgan Chase & Co. raised their target price on shares of BridgeBio Pharma from $89.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday. Barclays reaffirmed an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday. Finally, HC Wainwright increased their price target on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Twenty-three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $83.35.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.